Overview

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition characterized by excess fat accumulation in the liver due to metabolic dysfunction, not alcohol use. Previously known as NAFLD, MASLD is closely linked to obesity, type 2 diabetes, hypertension, and other features of metabolic syndrome. The disease ranges from simple steatosis to more severe forms like MASH (steatohepatitis), fibrosis, cirrhosis, and even liver cancer. Diagnosis typically involves imaging, blood tests, and sometimes liver biopsy to assess inflammation and scarring. Although there are no FDA-approved treatments yet, management focuses on weight loss, healthy diet, physical activity, and controlling related metabolic conditions. MASLD affects nearly 25–30% of adults globally and is a major cause of liver-related illness. Importantly, cardiovascular disease remains the leading cause of death in patients with MASLD, highlighting the need for comprehensive care.

MASLD is a treatable condition that can often be managed in the primary care setting. This webinar series strives to improve patient outcomes by increasing the knowledge, comprehension, and performance of primary care physicians in managing MASLD, especially when treating underserved populations.

Learning Objectives

• • Explain the natural history and progression of MASLD
  • Identify patients at risk of developing MASLD
  • Discuss diagnostic criteria for MASLD
  • Institute screening procedures for MASLD in patients with metabolic risk factors
  • Discuss a comprehensive management strategy for MASLD that incorporates lifestyle changes and the use of appropriate therapies such as GLP-1 receptor agonists and SGLT2 inhibitors.